Cargando…

Decreased Ficolin-3-mediated Complement Lectin Pathway Activation and Alternative Pathway Amplification During Bacterial Infections in Patients With Type 2 Diabetes Mellitus

Bacterial infections are frequent and severe in patients with diabetes mellitus. Whether diabetes per se induces functional alterations in the complement system hampering activation during infection is unknown. We investigated key elements of the complement system during bacterial infections in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Barkai, László József, Sipter, Emese, Csuka, Dorottya, Prohászka, Zoltán, Pilely, Katrine, Garred, Peter, Hosszúfalusi, Nóra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436462/
https://www.ncbi.nlm.nih.gov/pubmed/30949171
http://dx.doi.org/10.3389/fimmu.2019.00509
_version_ 1783406819125755904
author Barkai, László József
Sipter, Emese
Csuka, Dorottya
Prohászka, Zoltán
Pilely, Katrine
Garred, Peter
Hosszúfalusi, Nóra
author_facet Barkai, László József
Sipter, Emese
Csuka, Dorottya
Prohászka, Zoltán
Pilely, Katrine
Garred, Peter
Hosszúfalusi, Nóra
author_sort Barkai, László József
collection PubMed
description Bacterial infections are frequent and severe in patients with diabetes mellitus. Whether diabetes per se induces functional alterations in the complement system hampering activation during infection is unknown. We investigated key elements of the complement system during bacterial infections in patients with type 2 diabetes mellitus (T2DM) and compared them to non-diabetic (ND) individuals. Using a prospective design, we included 197 T2DM, and 196 ND subjects, all with clinical diagnosis of acute community-acquired bacterial infections. Functional activities of the ficolin-3-mediated lectin (F3-LP), mannose binding lectin-mediated lectin- (MBL-LP), classical (CP), and alternative pathways (AP), as well as concentrations of complement activation products C4d and sC5b-9 were determined. Functional in vitro activities of F3-LP and AP were significantly higher in T2DM than in ND subjects, (median 64% vs. 45%, p = 0.0354 and 75 vs. 28%, p = 0.0013, respectively), indicating a decreased in vivo activation and lack of consumption of F3-LP and AP in T2DM patients, whereas no difference in functional capacities of CP and MBL-LP were observed between T2DM and ND subjects. Diminished F3-LP and AP activation was most pronounced in diabetic patients with urinary tract infections with positive microbiological culture results for Escherichia coli bacteria. In the T2DM group 3-months mortality significantly associated with diminished F3-LP and AP, but not with CP activation. Concentrations of C4d and sC5b-9 were significantly lower in the T2DM than in ND patients. In conclusion, we found impaired F3-LP activation and lack of AP amplification during bacterial infections in patients with type 2 diabetes, compared to non-diabetic subjects, suggesting a diminished complement mediated protection to bacterial infections in T2DM.
format Online
Article
Text
id pubmed-6436462
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64364622019-04-04 Decreased Ficolin-3-mediated Complement Lectin Pathway Activation and Alternative Pathway Amplification During Bacterial Infections in Patients With Type 2 Diabetes Mellitus Barkai, László József Sipter, Emese Csuka, Dorottya Prohászka, Zoltán Pilely, Katrine Garred, Peter Hosszúfalusi, Nóra Front Immunol Immunology Bacterial infections are frequent and severe in patients with diabetes mellitus. Whether diabetes per se induces functional alterations in the complement system hampering activation during infection is unknown. We investigated key elements of the complement system during bacterial infections in patients with type 2 diabetes mellitus (T2DM) and compared them to non-diabetic (ND) individuals. Using a prospective design, we included 197 T2DM, and 196 ND subjects, all with clinical diagnosis of acute community-acquired bacterial infections. Functional activities of the ficolin-3-mediated lectin (F3-LP), mannose binding lectin-mediated lectin- (MBL-LP), classical (CP), and alternative pathways (AP), as well as concentrations of complement activation products C4d and sC5b-9 were determined. Functional in vitro activities of F3-LP and AP were significantly higher in T2DM than in ND subjects, (median 64% vs. 45%, p = 0.0354 and 75 vs. 28%, p = 0.0013, respectively), indicating a decreased in vivo activation and lack of consumption of F3-LP and AP in T2DM patients, whereas no difference in functional capacities of CP and MBL-LP were observed between T2DM and ND subjects. Diminished F3-LP and AP activation was most pronounced in diabetic patients with urinary tract infections with positive microbiological culture results for Escherichia coli bacteria. In the T2DM group 3-months mortality significantly associated with diminished F3-LP and AP, but not with CP activation. Concentrations of C4d and sC5b-9 were significantly lower in the T2DM than in ND patients. In conclusion, we found impaired F3-LP activation and lack of AP amplification during bacterial infections in patients with type 2 diabetes, compared to non-diabetic subjects, suggesting a diminished complement mediated protection to bacterial infections in T2DM. Frontiers Media S.A. 2019-03-20 /pmc/articles/PMC6436462/ /pubmed/30949171 http://dx.doi.org/10.3389/fimmu.2019.00509 Text en Copyright © 2019 Barkai, Sipter, Csuka, Prohászka, Pilely, Garred and Hosszúfalusi. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Barkai, László József
Sipter, Emese
Csuka, Dorottya
Prohászka, Zoltán
Pilely, Katrine
Garred, Peter
Hosszúfalusi, Nóra
Decreased Ficolin-3-mediated Complement Lectin Pathway Activation and Alternative Pathway Amplification During Bacterial Infections in Patients With Type 2 Diabetes Mellitus
title Decreased Ficolin-3-mediated Complement Lectin Pathway Activation and Alternative Pathway Amplification During Bacterial Infections in Patients With Type 2 Diabetes Mellitus
title_full Decreased Ficolin-3-mediated Complement Lectin Pathway Activation and Alternative Pathway Amplification During Bacterial Infections in Patients With Type 2 Diabetes Mellitus
title_fullStr Decreased Ficolin-3-mediated Complement Lectin Pathway Activation and Alternative Pathway Amplification During Bacterial Infections in Patients With Type 2 Diabetes Mellitus
title_full_unstemmed Decreased Ficolin-3-mediated Complement Lectin Pathway Activation and Alternative Pathway Amplification During Bacterial Infections in Patients With Type 2 Diabetes Mellitus
title_short Decreased Ficolin-3-mediated Complement Lectin Pathway Activation and Alternative Pathway Amplification During Bacterial Infections in Patients With Type 2 Diabetes Mellitus
title_sort decreased ficolin-3-mediated complement lectin pathway activation and alternative pathway amplification during bacterial infections in patients with type 2 diabetes mellitus
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436462/
https://www.ncbi.nlm.nih.gov/pubmed/30949171
http://dx.doi.org/10.3389/fimmu.2019.00509
work_keys_str_mv AT barkailaszlojozsef decreasedficolin3mediatedcomplementlectinpathwayactivationandalternativepathwayamplificationduringbacterialinfectionsinpatientswithtype2diabetesmellitus
AT sipteremese decreasedficolin3mediatedcomplementlectinpathwayactivationandalternativepathwayamplificationduringbacterialinfectionsinpatientswithtype2diabetesmellitus
AT csukadorottya decreasedficolin3mediatedcomplementlectinpathwayactivationandalternativepathwayamplificationduringbacterialinfectionsinpatientswithtype2diabetesmellitus
AT prohaszkazoltan decreasedficolin3mediatedcomplementlectinpathwayactivationandalternativepathwayamplificationduringbacterialinfectionsinpatientswithtype2diabetesmellitus
AT pilelykatrine decreasedficolin3mediatedcomplementlectinpathwayactivationandalternativepathwayamplificationduringbacterialinfectionsinpatientswithtype2diabetesmellitus
AT garredpeter decreasedficolin3mediatedcomplementlectinpathwayactivationandalternativepathwayamplificationduringbacterialinfectionsinpatientswithtype2diabetesmellitus
AT hosszufalusinora decreasedficolin3mediatedcomplementlectinpathwayactivationandalternativepathwayamplificationduringbacterialinfectionsinpatientswithtype2diabetesmellitus